Pancreatic Cell News 10.13 April 9, 2019 | |
| |
TOP STORYRing1b-Dependent Epigenetic Remodeling Is an Essential Prerequisite for Pancreatic Carcinogenesis Relevance of Ring1b-catalysed H2AK119ub in acinar cell reprogramming was studied in an inducible Ring1b knockout mouse model. CRISPR/Cas9-mediated Ring1b ablation as well as drug-induced Ring1b inhibition were functionally characterized in pancreatic cancer cells. [Gut] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)DIABETES & PANCREATITISGlucose Controls Glucagon Secretion by Directly Modulating cAMP in Alpha Cells Researchers investigated the role of the intracellular messenger cAMP in alpha-cell-intrinsic glucose regulation of glucagon release. Subplasmalemmal cAMP and Ca2+ concentrations were recorded in isolated and islet-located alpha cells using fluorescent reporters and total internal reflection microscopy. [Diabetologia] Full Article Scientists demonstrated translocation of glucose-regulated protein (GRP78) to the surface of human EndoC-βH1 cells and primary human islets upon cytokine exposure, in analogy to observations in rodent INS-1E and MIN6 beta cell lines. They demonstrated that both GRP78 signaling domains initiated pro-apoptotic signaling cascades in beta cells. [Cell Death Dis] Full Article INS-1 cells were incubated at a high-glucose concentration with various concentrations of troglitazone, rosiglitazone, pioglitazone, and lobeglitazone. Apoptosis and proliferation of beta cells, markers for ER stress and glucose-stimulated insulin secretion were assessed. [Diabetes Res Clin Pract] Abstract PANCREATIC CANCERNon-muscle myosin IIA (NMIIA) regulated β-catenin mediated EMT to promote the proliferation, migration, invasion, and sphere formation of pancreatic cancer cells in vitro and in vivo. NMIIA controlled the β-catenin transcriptional activity by interacting with β-catenin. Moreover, MEK/ERK signaling was critical in MLC2 phosphorylation, which could mediate NMIIA activity and regulate Wnt/β-catenin signaling. [Oncogene] Abstract Primary human pancreatic ductal adenocarcinoma (PDAC) cultures were treated with conditioned media (CM) from monocyte-derived macrophage cultures incubated with apoptotic PDAC cells (MØApopCM). MØApopCM pretreatment rendered naïve PDAC cells resistant to gemcitabine- or abraxane-induced apoptosis. [Oncogene] Abstract Investigators report that CD90 was expressed on both stromal and tumor cells and that high expression of CD90 was related to a poor prognosis in patients with pancreatic ductal adenocarcinoma (PDAC). The CD90 highly expressed population in PDAC cells harbored high stemness features and tumorigenicity. [Cancer Lett] Abstract Mechanistically, ARHGAP4 interacted with and ubiquitinates histone deacetylase 2 (HDAC2), which in turn inhibited β-catenin activation. Furthermore, treatment of CAY10683, a HDAC2 inhibitor, and XAV939, a Wnt/β-catenin pathway inhibitor, attenuated the effects of ARHGAP4 silencing on pancreatic cancer cells. [Carcinogenesis] Abstract Scientists demonstrated that LIM and SH3 protein 2 (LASP2) was downregulated in pancreatic cancer (PC) tissues and cell lines. In addition, upregulation of LASP2 inhibited PC cell migration and invasion. They also found that LASP2 upregulation reversed tumor growth factor-β (TGF-β)-induced epithelial-mesenchymal transition (EMT) in PC cells. [J Cell Biochem] Abstract Ocoxin oral solution (OOS) enhanced the cytotoxic effect of paclitaxel and gemcitabine, while it ameliorated the chemoresistance induced by fibroblast-derived soluble factors in human pancreatic cancer cells. The OOS also promoted the regulation of the expression of genes that were altered in pancreatic carcinoma and slowed down 266-6 cell pancreatic tumor development in vivo. [Pancreas] Abstract Subscribe to one of our other 19 science newsletters such as Hepatic Cell News & Intestinal Cell News. | |
| |
REVIEWSRole of the P2X7 Receptor in the Pathogenesis of Type 2 Diabetes and Its Microvascular Complications P2X7 receptors can be found in many tissues and organs, where they mediate several biological functions. The authors summarize the current knowledge about the role of this receptor in the pathogenesis of type 2 diabetes, in which the key clinical features are impaired insulin secretion and sensitivity, hyperglycemia, coexistence of other cardiovascular risk factors such as dyslipidemia and hypertension, and subclinical inflammation. [Curr Opin Pharmacol] Abstract Deciphering Role of FGFR Signaling Pathway in Pancreatic Cancer Investigators describe recent advances of the FGFR signaling pathway in pancreatic carcinogenesis and progression. Moreover, they highlight the available chemical inhibitors of the FGFR pathway for potential treatment of pancreatic cancer. [Cell Prolif] Full Article Visit our reviews page to see a complete list of reviews in the pancreatic cell research field. | |
| |
SCIENCE NEWSMoleculin Announces Preclinical Pancreatic Cancer Data Presented Moleculin Biotech, Inc. announced that preclinical data supporting activity of its STAT3-inhibiting Immune/Transcription Modulators was presented by Dr. Waldemar Priebe, Founder and Chair of the Scientific Advisory Board of Moleculin, Inc. [Press release from Moleculin Biotech, Inc. discussing research presented at the 2019 Annual Meeting of the American Association for Cancer Research (AACR), Atlanta] Press Release Clovis Oncology, Inc. announced multiple presentations. These include presentation of interim results from an investigator-initiated Phase II trial of Rubraca® in platinum-sensitive patients with advanced pancreatic cancer. [Press release from Clovis Oncology, Inc. discussing research presented at the 2019 Annual Meeting of the American Association for Cancer Research (AACR), Atlanta] Press Release | |
| |
INDUSTRY NEWSImmunovia announced that Prof. Stephen Pereira and his team at the institute for Liver and Digestive Health, University College London will extend the prospective collection of blood samples funded by Immunovia and that started with the PanSYM-1 pilot study. [Immunovia] Press Release Sun Pharma Launches Ready-to-Infuse INFUGEM in the US Sun Pharmaceutical Industries Ltd. announced that INFUGEM™, for intravenous use, is now commercially available in the US. INFUGEM, the first chemotherapy product that comes in a premixed, ready-to-infuse formulation, was approved by the FDA in July 2018 in combination with other drugs for the treatment of breast, ovarian, non-small cell lung cancers, and as a single agent for the treatment of pancreatic cancer. [Sun Pharmaceutical Industries Ltd.(Business Wire, Inc.)] Press Release POXEL SA and Sumitomo Dainippon Pharma Co., Ltd, announced positive top-line Phase III data results for the Imeglimin TIMES 1 trial for the treatment of type 2 diabetes in Japan. Referred to as TIMES (Trials of IMeglimin for Efficacy and Safety), the Imeglimin Phase III program in Japan includes three pivotal trials to evaluate Imeglimin’s efficacy and safety in over 1,100 patients. [POXEL SA] Press Release Adocia announced positive topline pharamacodynamic and safety results from the first Phase I study of ADOO0, a ready-to-use, pH 4, co-formulation at fixed ratio of pramlintide, the only FDA-approved analog of amylin, and A12G human insulin analog, a rapid-acting insulin that is known to be the main circulating metabolite of insulin glargine. [Adocia] Press Release | |
| |
POLICY NEWSRacism Rife at Top South African University, Says Report A damning report that says racism is entrenched at the University of Cape Town has reignited discussions about how to erase the divisive legacy of colonialism at South Africa’s top research institutions. [Nature News] Editorial FDA, New York Attorney General Go After Stem Cell Clinics On April 3, the FDA sent letters to 20 companies providing stem cell treatments, reports The New York Times, reminding them that they may require FDA approval and should take action to comply. The agency also issued a warning to a stem cell company for violating good manufacturing practices. [The Scientist] Editorial
| |
EVENTSNEW Keystone Symposia: Cancer Stem Cells: Advances in Biology & Clinical Translation Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Research Affiliate – Pancreatic Cancer Research (Roswell Park) NEW Clinical Professor – Diabetes (Univesity of Southern Denmark) Postdoctoral Researcher – Beta-Cell Regeneration in Zebrafish (Karolinska Institutet) PhD Position – Pancreatic Cancer (Philipps-Universität Marburg) Research Positions – Pancreatic Beta-Cells (Université de Montréal) Postdoctoral Position – Diabetes (University of Minnesota) Postdoctoral Fellow – Pancreatic Development & Islet Biology (Vanderbilt University) Postdoctoral Fellow – Neuroscience and Diabetes (The Child Health Institute of New Jersey) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Pancreatic Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|